Recent News
Oral Drug Combination Eases Treatment Burden for AML Patients
The ASCERTAIN V clinical trial demonstrated that an all-oral drug combination for older patients with acute myeloid leukemia (AML) is an effective alternative to the current standard, which requires repeated hospital or office visits for intravenous treatment.
NewYork-Presbyterian Announces Applications Are Open for the 2026 Community Fund
NewYork-Presbyterian today announced a Request for Proposals (RFP) for the Community Fund, the hospital’s largest grant opportunity for community-based organizations (CBOs).
New Cholesterol Guidelines Aim to Stop Heart Disease Earlier
Doctors should consider treating high cholesterol much earlier and more aggressively than they have in the past, according to a new perspective by Weill Cornell Medicine, NewYork-Presbyterian and Yale School of Medicine investigators.
NewYork-Presbyterian Achieves 5-Star Rating from CMS for High-Quality Care
All NewYork-Presbyterian hospitals now have a five-star rating from the Centers for Medicare & Medicaid Services (CMS), the highest rating in CMS’s annual quality measurement program for hospitals.
Featured Stories
